Search
Menu
BAE Systems Sensor Solutions - Fairchild - Thermal Imaging Solutions 4/24 LB

Virtual Biomarkers: An Emerging High-Throughput Research Tool

Aug 11, 2022
Facebook X LinkedIn Email
TO VIEW THIS WEBINAR:
Login  Register
About This Webinar
Pathology underlies every facet of health care, influencing more than 70% of all medical decisions. It is used in every phase of pre-clinical and clinical drug development, in every tumor repository and biobank, and in an increasing majority of standard and companion diagnostics for precision cancer care. However, such studies, whether performed traditionally via visual microscopy or via newer artificial intelligence (AI)-enhanced image analyses, are limited by the number of markers that can be performed on dwindling and aging samples. These samples must also be preserved for downstream multiomics analysis.

Yair Rivenson demonstrates how it is possible to alter the centuries-old practice of histopathology using a digitized process in a nondestructive fashion. The process is enabled by a machine learning-based virtual staining technology that allows fully digital and virtual multiplex tissue platforms to substantively improve the quality and quantity of a pathology sample. This is accomplished by protecting the sample integrity, minimizing the pre-analytic degradation of target analytes, and revolutionizing the storage and processing of the cancer-relevant biospecimens.

Rivenson also discusses the additional benefits of the technology. These benefits include lab sustainability and digital outputs that can be seamlessly integrated into downstream AI image-analysis software, thereby providing total characterization of cellular processes within minutes.

Who should attend:
Researchers and engineers working in pathology who are interested in recent progress within the field. Professionals working with AI in biophotonics fields. Those interested in test and measurement, imaging, microscopy, and spectroscopy, in industries such as cancer research, histopathology, medical, and pharmaceutical.

About the presenter:
Yair Rivenson, Ph.D., is CEO and co-founder of Pictor Labs. Prior to taking an active role in Pictor Labs, he served as an adjunct and research professor at the UCLA Department of Electrical and Computer Engineering. There, Rivenson developed the core technologies that would become Pictor’s foundation. He transitioned to his faculty position following three years of postdoctoral work in professor Aydogan Ozcan’s lab at UCLA.

Rivenson's IP portfolio includes one granted patent and 11 pending patents, over 65 co-authored journal publications and more than 110 peer-reviewed conference presentations. His achievements have been recognized by senior membership from both IEEE and Optica, as well as UCLA’s Chancellor’s Award for postdoctoral students. Rivenson serves as a senior editor of the IEEE Photonics Journal.

Research & TechnologyMicroscopyartificial intelligenceBiophotonicscancermedicalpharmaceutical
We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.